

Jan A Walewski

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9215005/jan-a-walewski-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117
papers

8,239
citations

30
h-index

90
g-index

127
ext. papers

9,546
ext. citations

6
avg, IF

4.88
L-index

#	Paper	IF	Citations
117	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group. <i>Lancet Oncology, The</i> , 2006 , 7, 379-91	21.7	1567
116	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. <i>Blood</i> , 2005 , 105, 1417-23	2.2	812
115	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MINT) Group. <i>Lancet Oncology, The</i> , 2011 , 12, 1013-22	21.7	485
114	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015 , 385, 1853-62	40	462
113	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 331-344	59.2	378
112	Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. <i>Blood</i> , 2008 , 111, 1094-100 ²	2.2	327
111	Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. <i>New England Journal of Medicine</i> , 2007 , 357, 1916-27	59.2	324
110	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017 , 390, 555-566	40	303
109	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2492-9	2.2	291
108	Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 424-35	21.7	248
107	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet, The</i> , 2016 , 388, 565-75	40	233
106	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008 , 111, 5486-95	2.2	223
105	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. <i>Blood</i> , 2010 , 115, 3215-23	2.2	200
104	Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. <i>Blood</i> , 2014 , 124, 3870-9	2.2	188
103	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i> , 2008 , 112, 2248-60	2.2	165
102	Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. <i>Blood</i> , 2002 , 99, 4379-85	2.2	164
101	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013 , 24, 561-76	10.3	162

100	Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. <i>Lancet Oncology, The</i> , 2008 , 9, 435-44	21.7	139
99	Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , 2005 , 23, 9208-18	2.2	115
98	Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1338-46	2.2	112
97	Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. <i>Blood</i> , 2018 , 132, 2639-2642	2.2	105
96	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. <i>Lancet Oncology, The</i> , 2016 , 17, 319-331	21.7	103
95	Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1624-30	2.2	99
94	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2011 , 12, 773-84	21.7	84
93	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016 , 91, 575-80	7.1	60
92	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020 , 135, 735-742	2.2	54
91	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018 , 29, 544-562	10.3	42
90	Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement. <i>Medical Oncology</i> , 2011 , 28, 1589-95	3.7	33
89	Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. <i>British Journal of Haematology</i> , 2010 , 150, 58-71	4.5	33
88	Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. <i>Blood</i> , 2014 , 123, 3255-62	2.2	31
87	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 248-256	2.2	29
86	Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 781-91	6.2	27
85	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2226-36	1.9	27
84	Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. <i>Journal of Clinical Immunology</i> , 2007 , 27, 339-46	5.7	27
83	A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. <i>Modern Pathology</i> , 2018 , 31, 732-743	9.8	23

82	Primary mediastinal large B-cell lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 273-83	4.4	23
81	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. <i>Haematologica</i> , 2016 , 101, 235-40	6.6	21
80	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2071-6	1.9	21
79	Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1670-6	4.7	21
78	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Group. <i>Blood</i> , 2016 , 127, 16-21	2.2	21
77	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021 , 8, e410-e421	14.6	20
76	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016 , 175, 860-867	4.5	18
75	Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. <i>Medical Oncology</i> , 2012 , 29, 2966-77	3.7	17
74	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. <i>Cancer</i> , 2008 , 113, 367-75	6.4	17
73	Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2005 , 156, 114-21		15
72	Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. <i>Blood</i> , 2015 , 126, 3172-3172	2.2	15
71	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1814-1828	1.9	15
70	Current Treatment of Chronic Lymphocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 5	5.4	14
69	Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 67	22.4	14
68	FcRIIA and FcRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1604-6	1.9	13
67	Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. <i>European Journal of Cancer</i> , 2018 , 104, 127-136	7.5	13
66	miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma. <i>Tumor Biology</i> , 2015 , 36, 5377-88	2.9	12
65	Human regulatory T cells suppress proliferation of B lymphoma cells. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1903-20	1.9	12

64	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020 , 133, 120-130	7.5	11
63	Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma. <i>Medical Oncology</i> , 2012 , 29, 2143-7	3.7	11
62	First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. <i>British Journal of Haematology</i> , 2020 , 188, 898-906	4.5	11
61	Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 675-684	1.9	11
60	Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator's Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study. <i>Blood</i> , 2014 , 124, 626-626	2.2	10
59	Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. <i>British Journal of Haematology</i> , 2018 , 183, 400-410	4.5	10
58	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016 , 47, 39-85	0.4	8
57	Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma. <i>Clinical Biochemistry</i> , 2010 , 43, 604-8	3.5	8
56	Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. <i>American Journal of Therapeutics</i> , 2016 , 23, e749-56	1	8
55	Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 180, 224-235	4.5	8
54	Lenalidomide potentiates CD4CD25Treg-related suppression of lymphoma B-cell proliferation. <i>Clinical and Experimental Medicine</i> , 2017 , 17, 193-207	4.9	7
53	Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis. <i>Annals of Hematology</i> , 2013 , 92, 925-33	3	7
52	The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 594-600	1.9	7
51	A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival. <i>Medical Oncology</i> , 2011 , 28, 194-8	3.7	7
50	Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapy. <i>Cytokines, Cellular & Molecular Therapy</i> , 2002 , 7, 15-24		7
49	Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2356-2362	1.9	6
48	Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma. <i>Tumor Biology</i> , 2012 , 33, 1733-8	2.9	6
47	Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. <i>Clinical Drug Investigation</i> , 2009 , 29, 491-513	3.2	6

46	Unusual cyclin D1 positive marginal zone lymphoma of mediastinum. <i>Medical Oncology</i> , 2006 , 23, 423-8	3.7	6
45	Mantle cell lymphoma presenting with paraproteinemia. <i>Medical Oncology</i> , 2005 , 22, 319-23	3.7	6
44	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021 , 148, 411-421	7.5	6
43	PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4 T Cells. <i>Cancers</i> , 2021 , 13,	6.6	6
42	Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant. <i>Leukemia and Lymphoma</i> , 2013 , 54, 973-8	1.9	5
41	Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas. <i>Cancers</i> , 2019 , 11,	6.6	5
40	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021 , 5, 5098-5106	7.8	5
39	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2013. <i>Acta Haematologica Polonica</i> , 2013 , 44, 3-47	0.4	4
38	Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis. <i>Chemotherapy</i> , 2013 , 59, 280-9	3.2	4
37	CHOP-21 for unfavorable Hodgkin's lymphoma. An exploratory study. <i>Medical Oncology</i> , 2010 , 27, 262-7	3.7	4
36	Unusual IgD+/CD38-follicular lymphoma with leukemic presentation. <i>Medical Oncology</i> , 2006 , 23, 131-5	3.7	4
35	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205). <i>Blood</i> , 2020 , 136, 22-23	2.2	4
34	Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group. <i>Polish Archives of Internal Medicine</i> , 2015 , 125, 741-8	1.9	4
33	Aggressive B-cell lymphoma: chasing the target. <i>Journal of Investigative Medicine</i> , 2020 , 68, 331-334	2.9	4
32	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2017. <i>Acta Haematologica Polonica</i> , 2017 , 48, 55-103	0.4	3
31	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012 , 43, 7-47	0.4	3
30	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Blood</i> , 2020 , 136, 26-28	2.2	3
29	Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network. <i>Blood</i> , 2021 , 138, 280-289	2.2	3

28	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2868-2875	1.9	3
27	Population-based epidemiological data of follicular lymphoma in Poland: 15 years of observation. <i>Scientific Reports</i> , 2020 , 10, 14610	4.9	3
26	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2931-2938	1.9	3
25	Significance of CD10 protein expression in the diagnostics of follicular lymphoma: A comparison of conventional immunohistochemistry with flow cytometry supported by the establishment of BCL2 and BCL6 rearrangements. <i>International Journal of Laboratory Hematology</i> , 2020 , 42, 453-463	2.5	2
24	Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis. <i>Leukemia and Lymphoma</i> , 2013 , 54, 790-3	1.9	2
23	European MCL Network: An Update on Current First Line Trials.. <i>Blood</i> , 2007 , 110, 388-388	2.2	2
22	Comparison of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients. <i>Annals of Transplantation</i> , 2013 , 18, 336-41	1.4	2
21	Higher genome variability within metabolism genes associates with recurrent <i>Clostridium difficile</i> infection. <i>BMC Microbiology</i> , 2021 , 21, 36	4.5	2
20	EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment. <i>Anticancer Research</i> , 2020 , 40, 6685-6697	2.3	1
19	Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy. <i>Medical Oncology</i> , 1996 , 13, 199-205	3.7	1
18	CHOP Chemotherapy for Unfavorable or Advanced Hodgkin's Lymphoma. A Pilot Study.. <i>Blood</i> , 2004 , 104, 1311-1311	2.2	1
17	Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution. <i>Blood</i> , 2014 , 124, 1640-1640	2.2	1
16	Significance of a Critical Set of 11q Chromosome Aberrations for Diagnosis of MYC Negative Burkitt Lymphoma. <i>Blood</i> , 2015 , 126, 2679-2679	2.2	1
15	DA-EPOCH-R Is an Effective Regimen in High Grade B-Cell Lymphoma Defined By Cell-of-Origin, Karyotype and BCL2/MYC/BCL6 Status and Expression. <i>Blood</i> , 2016 , 128, 1754-1754	2.2	1
14	The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies. <i>Blood</i> , 2021 , 138, 1549-1549	2.2	1
13	PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma. <i>Pathology Research and Practice</i> , 2020 , 216, 153096	3.4	1
12	Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. <i>BMC Cancer</i> , 2020 , 20, 1088	4.8	1
11	Efficacy of siltuximab in the treatment of idiopathic multicentric castlemans disease, the first Polish, real-world experience with long-term observation. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3031-3034	1.9	1

10	Isolation and characteristics of dendritic cell progenitors from the bone marrow of the Hodgkin's disease patients. <i>Advances in Experimental Medicine and Biology</i> , 1995 , 378, 553-5	3.6	1
9	Fine Needle Aspiration Biopsy with Flow Cytometry Is a Reliable Method for Defining Immunophenotype of Prognostic Value in T Lymphoblastic Lymphoma.. <i>Blood</i> , 2009 , 114, 3928-3928	2.2	0
8	Zalecenia Polskiej Grupy Szpiczakowej dotyczce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2015. <i>Acta Haematologica Polonica</i> , 2015 , 46, 159-211	0.4	
7	Follow-up in aggressive lymphomas. <i>Memo - Magazine of European Medical Oncology</i> , 2014 , 7, 80-82	0.3	
6	Chbniak z komtek pszcza u pacjentw niekwalifikujcych si do chemioterapii w wysokich dawkach. <i>Acta Haematologica Polonica</i> , 2013 , 44, 104-109	0.4	
5	Moliwoci leczenia indukcyjnego chorych na szpiczaka plazmocytoowego kwalifikujcych si do chemioterapii wysokodawkowanej wspomaganej autologiczn transplantacj komtek krwiotwrczych a aktualne zalecenia Polskiej Grupy Szpiczakowej. <i>Acta Haematologica Polonica</i> , 2017 , 48, 101-111	0.4	
4	Chbniaki agresywne z komtek B z podwjnym translokacj Double/triple hit lymphoma. <i>Acta Haematologica Polonica</i> , 2015 , 46, 263-268	0.4	
3	Wczesna niehematologiczna toksyczno po chemioterapii w wysokich dawkach i autologicznym przeszczepieniu komtek krwiotwrczych u chorych na nowotwory limfoidalne powyj 60. roku cia. <i>Acta Haematologica Polonica</i> , 2012 , 43, 210-214	0.4	
2	Monoclonal antibody therapy for classical Hodgkin lymphoma. <i>Clinical Investigation</i> , 2013 , 3, 899-910		
1	Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs. <i>BioMed Research International</i> , 2021 , 2021, 3212878		3